All In Biotech

NDA 215390 · Teva

Igalmi

Dexmedetomidine Hydrochloride · Buccal, Sublingual · Central alpha-2 Adrenergic Agonist

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Apr 5, 2022

Approved uses

3

Original approval plus efficacy supplements

Registered trials

1,922

279 Phase 3, 159 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Therapeutic areas: Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • IGALMI · DEXMEDETOMIDINE HYDROCHLORIDE EQ 0.18MG BASE · FILM, BUCCAL, SUBLINGUAL · Prescription
  • IGALMI · DEXMEDETOMIDINE HYDROCHLORIDE EQ 0.12MG BASE · FILM, BUCCAL, SUBLINGUAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Dexmedetomidine" as an intervention, any sponsor and status, largest first.

All 1,922 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Igalmi (Dexmedetomidine HCl)

2024 spending

$309K

Beneficiaries

42

97 claims

Per beneficiary

$7,357

$108.78 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$64,689
2024$308,999

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,906 on PubMed

Sponsor: Teva

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.